AAPL294.30-2.71 (-0.91%) ▼|ABBV234.76+4.75 (+2.07%) ▲|ABT90.53+2.70 (+3.07%) ▲|ACN127.01+2.18 (+1.75%) ▲|ADBE197.43+2.53 (+1.30%) ▲|AMAT585.88-54.30 (-8.48%) ▼|AMD519.85-31.78 (-5.76%) ▼|AMGN347.01+2.29 (+0.66%) ▲|AMT179.38+2.95 (+1.67%) ▲|AMZN234.11+1.32 (+0.57%) ▲|AVGO380.15-11.98 (-3.06%) ▼|AXP337.78-0.29 (-0.09%) ▼|BA216.71-4.12 (-1.87%) ▼|BAC57.91+0.54 (+0.94%) ▲|BKNG168.94+1.17 (+0.70%) ▲|BLK1,015.33-36.41 (-3.46%) ▼|BMY55.53+0.83 (+1.52%) ▲|BNY147.29+0.85 (+0.58%) ▲|BRK-B492.81+4.12 (+0.84%) ▲|C144.97-0.70 (-0.48%) ▼|CAT984.24-38.04 (-3.72%) ▼|CL91.43+2.76 (+3.11%) ▲|CMCSA22.80+0.48 (+2.15%) ▲|COF197.81-2.89 (-1.44%) ▼|COP109.97+0.27 (+0.25%) ▲|COST957.68+6.33 (+0.67%) ▲|CRM153.42+3.30 (+2.20%) ▲|CSCO121.15-0.38 (-0.31%) ▼|CVS101.57+0.27 (+0.27%) ▲|CVX175.98+0.92 (+0.53%) ▲|DE591.94-6.65 (-1.11%) ▼|DHR178.97+0.78 (+0.44%) ▲|DIS103.53+1.08 (+1.05%) ▲|DUK125.05+1.53 (+1.24%) ▲|EMR143.14-7.07 (-4.71%) ▼|FDX317.24-11.54 (-3.51%) ▼|GD350.34+6.98 (+2.03%) ▲|GE356.47+1.35 (+0.38%) ▲|GEV1,034.98-92.61 (-8.21%) ▼|GILD125.05+0.18 (+0.14%) ▲|GM78.95-1.48 (-1.84%) ▼|GOOG346.08-2.70 (-0.77%) ▼|GOOGL346.13-3.43 (-0.98%) ▼|GS1,094.44-11.93 (-1.08%) ▼|HD324.45-2.17 (-0.66%) ▼|HON222.37-5.74 (-2.52%) ▼|IBM264.94+12.72 (+5.04%) ▲|INTC132.28-8.66 (-6.14%) ▼|INTU258.05+0.28 (+0.11%) ▲|ISRG403.18+0.23 (+0.06%) ▲|JNJ239.08+7.79 (+3.37%) ▲|JPM334.14+2.66 (+0.80%) ▲|KO80.31+0.78 (+0.98%) ▲|LIN512.26-4.45 (-0.86%) ▼|LLY1,107.08+5.00 (+0.45%) ▲|LMT503.67+10.07 (+2.04%) ▲|LOW213.54-0.86 (-0.40%) ▼|LRCX371.33-38.21 (-9.33%) ▼|MA488.07+3.98 (+0.82%) ▲|MCD271.66+1.56 (+0.58%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.63+1.36 (+1.72%) ▲|META562.20-1.65 (-0.29%) ▼|MMM161.84-1.38 (-0.85%) ▼|MO71.61+2.10 (+3.02%) ▲|MRK119.60+4.12 (+3.57%) ▲|MS226.03-1.06 (-0.47%) ▼|MSFT373.94+6.60 (+1.80%) ▲|MU1,051.77-159.61 (-13.18%) ▼|NEE86.43+0.35 (+0.41%) ▲|NFLX72.82-0.06 (-0.08%) ▼|NKE42.38-0.81 (-1.88%) ▼|NOW95.94+2.93 (+3.15%) ▲|NVDA200.04-8.61 (-4.13%) ▼|ORCL165.16-9.91 (-5.66%) ▼|PEP142.05+1.34 (+0.95%) ▲|PFE24.72-0.36 (-1.44%) ▼|PG150.86+3.18 (+2.15%) ▲|PLTR116.70-2.80 (-2.34%) ▼|PM178.69+5.52 (+3.19%) ▲|QCOM204.13-17.77 (-8.01%) ▼|RTX186.39+4.56 (+2.51%) ▲|SBUX101.05+0.90 (+0.90%) ▲|SCHW93.17+1.14 (+1.24%) ▲|SO94.93+1.50 (+1.61%) ▲|SPG216.74+2.17 (+1.01%) ▲|T22.81+0.71 (+3.21%) ▲|TMO469.35+5.34 (+1.15%) ▲|TMUS184.57+4.51 (+2.50%) ▲|TSLA381.61-23.44 (-5.79%) ▼|TXN304.36-27.92 (-8.40%) ▼|UBER69.67-1.76 (-2.46%) ▼|UNH409.25+2.57 (+0.63%) ▲|UNP258.61-1.30 (-0.50%) ▼|UPS105.83-1.41 (-1.31%) ▼|USB60.05+1.37 (+2.33%) ▲|V328.48+1.88 (+0.58%) ▲|VZ46.73+1.37 (+3.02%) ▲|WFC84.13+0.29 (+0.35%) ▲|WMT119.42+2.24 (+1.91%) ▲|XOM139.73+1.26 (+0.91%) ▲|AAPL294.30-2.71 (-0.91%) ▼|ABBV234.76+4.75 (+2.07%) ▲|ABT90.53+2.70 (+3.07%) ▲|ACN127.01+2.18 (+1.75%) ▲|ADBE197.43+2.53 (+1.30%) ▲|AMAT585.88-54.30 (-8.48%) ▼|AMD519.85-31.78 (-5.76%) ▼|AMGN347.01+2.29 (+0.66%) ▲|AMT179.38+2.95 (+1.67%) ▲|AMZN234.11+1.32 (+0.57%) ▲|AVGO380.15-11.98 (-3.06%) ▼|AXP337.78-0.29 (-0.09%) ▼|BA216.71-4.12 (-1.87%) ▼|BAC57.91+0.54 (+0.94%) ▲|BKNG168.94+1.17 (+0.70%) ▲|BLK1,015.33-36.41 (-3.46%) ▼|BMY55.53+0.83 (+1.52%) ▲|BNY147.29+0.85 (+0.58%) ▲|BRK-B492.81+4.12 (+0.84%) ▲|C144.97-0.70 (-0.48%) ▼|CAT984.24-38.04 (-3.72%) ▼|CL91.43+2.76 (+3.11%) ▲|CMCSA22.80+0.48 (+2.15%) ▲|COF197.81-2.89 (-1.44%) ▼|COP109.97+0.27 (+0.25%) ▲|COST957.68+6.33 (+0.67%) ▲|CRM153.42+3.30 (+2.20%) ▲|CSCO121.15-0.38 (-0.31%) ▼|CVS101.57+0.27 (+0.27%) ▲|CVX175.98+0.92 (+0.53%) ▲|DE591.94-6.65 (-1.11%) ▼|DHR178.97+0.78 (+0.44%) ▲|DIS103.53+1.08 (+1.05%) ▲|DUK125.05+1.53 (+1.24%) ▲|EMR143.14-7.07 (-4.71%) ▼|FDX317.24-11.54 (-3.51%) ▼|GD350.34+6.98 (+2.03%) ▲|GE356.47+1.35 (+0.38%) ▲|GEV1,034.98-92.61 (-8.21%) ▼|GILD125.05+0.18 (+0.14%) ▲|GM78.95-1.48 (-1.84%) ▼|GOOG346.08-2.70 (-0.77%) ▼|GOOGL346.13-3.43 (-0.98%) ▼|GS1,094.44-11.93 (-1.08%) ▼|HD324.45-2.17 (-0.66%) ▼|HON222.37-5.74 (-2.52%) ▼|IBM264.94+12.72 (+5.04%) ▲|INTC132.28-8.66 (-6.14%) ▼|INTU258.05+0.28 (+0.11%) ▲|ISRG403.18+0.23 (+0.06%) ▲|JNJ239.08+7.79 (+3.37%) ▲|JPM334.14+2.66 (+0.80%) ▲|KO80.31+0.78 (+0.98%) ▲|LIN512.26-4.45 (-0.86%) ▼|LLY1,107.08+5.00 (+0.45%) ▲|LMT503.67+10.07 (+2.04%) ▲|LOW213.54-0.86 (-0.40%) ▼|LRCX371.33-38.21 (-9.33%) ▼|MA488.07+3.98 (+0.82%) ▲|MCD271.66+1.56 (+0.58%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.63+1.36 (+1.72%) ▲|META562.20-1.65 (-0.29%) ▼|MMM161.84-1.38 (-0.85%) ▼|MO71.61+2.10 (+3.02%) ▲|MRK119.60+4.12 (+3.57%) ▲|MS226.03-1.06 (-0.47%) ▼|MSFT373.94+6.60 (+1.80%) ▲|MU1,051.77-159.61 (-13.18%) ▼|NEE86.43+0.35 (+0.41%) ▲|NFLX72.82-0.06 (-0.08%) ▼|NKE42.38-0.81 (-1.88%) ▼|NOW95.94+2.93 (+3.15%) ▲|NVDA200.04-8.61 (-4.13%) ▼|ORCL165.16-9.91 (-5.66%) ▼|PEP142.05+1.34 (+0.95%) ▲|PFE24.72-0.36 (-1.44%) ▼|PG150.86+3.18 (+2.15%) ▲|PLTR116.70-2.80 (-2.34%) ▼|PM178.69+5.52 (+3.19%) ▲|QCOM204.13-17.77 (-8.01%) ▼|RTX186.39+4.56 (+2.51%) ▲|SBUX101.05+0.90 (+0.90%) ▲|SCHW93.17+1.14 (+1.24%) ▲|SO94.93+1.50 (+1.61%) ▲|SPG216.74+2.17 (+1.01%) ▲|T22.81+0.71 (+3.21%) ▲|TMO469.35+5.34 (+1.15%) ▲|TMUS184.57+4.51 (+2.50%) ▲|TSLA381.61-23.44 (-5.79%) ▼|TXN304.36-27.92 (-8.40%) ▼|UBER69.67-1.76 (-2.46%) ▼|UNH409.25+2.57 (+0.63%) ▲|UNP258.61-1.30 (-0.50%) ▼|UPS105.83-1.41 (-1.31%) ▼|USB60.05+1.37 (+2.33%) ▲|V328.48+1.88 (+0.58%) ▲|VZ46.73+1.37 (+3.02%) ▲|WFC84.13+0.29 (+0.35%) ▲|WMT119.42+2.24 (+1.91%) ▲|XOM139.73+1.26 (+0.91%) ▲|
20.2 C
New York
Wednesday, June 24, 2026

Tag: treatments

newssourceFORcompanyinformationcontent1marketreleases

$615.14 Mn Hair Botox Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

The hair botox market sees opportunities in rising consumer demand for natural, safe hair treatments and at-home solutions. The shift toward chemical-free options addresses safety concerns linked to traditional methods. Companies focus on R&D for innovative products offering immediate benefits, boosting growth. 
The hair botox market sees opportunities in rising consumer demand for natural, safe hair treatments and at-home solutions. The shift toward chemical-free options addresses safety concerns linked to traditional methods. Companies focus on R&D for innovative products offering immediate benefits, boosting growth.

SanMelix announces the addition of Mr. Ajay Dhaul to our Board of Directors and Executive Leadership team in the role of Chief Strategy &...

Poinciana, Fl, June 20, 2025 (GLOBE NEWSWIRE) -- SanMelix, the company behind BeeCure Radiation Burn Relief Cream, is excited to announce the addition of Mr. Ajay Dhaul to our Board of Directors and Executive Leadership team in the role of Chief Strategy & Growth Officer, effective June 9, 2025.

Over $7.7M in Ontario-Based Platforms to Advance Open Science and Brain Health Innovation

Two cutting-edge platforms at CAMH and Western University aim to accelerate AI-driven brain research and global data sharing TORONTO, June 20, 2025 /CNW/ - Brain Canada...

SRPT INQUIRY: Sarepta Therapeutics, Inc. Investors that Lost Money may have been Affected by Fraud — Contact BFA Law (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law about its ongoing securities fraud investigation.

Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia

Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia Findings Presented at...

13 Press Releases You Need to See This Week

Including the launch of two Netflix Houses, TI's $60B semiconductor investment,Americans' favorite road trip snacks and the debut of Trump Mobile.  NEW YORK, June 20,...

Biomarkers and New Therapeutic Strategies to Better Treat Brain Cancer

INRS Professor receives $1.2M to advance glioblastoma research  LAVAL, QC, June 20, 2025 /CNW/ - Professor Maya Saleh, a world-renowned expert in immuno-oncology at the Institut national...

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.3,4 A final decision on the approval in the European Union is expected in the coming months.

So-Young Announces Extension of Plan to Implement ADS Ratio Change

BEIJING, June 20, 2025 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers...

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub (“HTH”) Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies1, HTH is operated by the Advanced Regenerative Manufacturing Institute (“ARMI”) and its BioFabUSA initiative.

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Cochlear celebrates 30 Years in China and the launch of the world’s first and only smart hearing implant system

The new Cochlear™ Nucleus® Nexa™ System is the first and only hearing implant featuring internal memory and upgradeable firmware.1+This year marks the 30-year anniversary since...

HealthRX Expands Telehealth Website Experience to Include GLP-1 Weight Loss Solutions, Prescription Access, and 24/7 Wellness Support

HealthRX enhances online platform to offer doctor-prescribed GLP-1 medications like Ozempic® and Zepbound® for adults seeking virtual weight loss support, prescription access, and 24/7 telehealth care 
HealthRX enhances online platform to offer doctor-prescribed GLP-1 medications like Ozempic® and Zepbound® for adults seeking virtual weight loss support, prescription access, and 24/7 telehealth care

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatments

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers